Target intelligence / Profile preview

Muscarinic acetylcholine receptor M1 and Muscarinic acetylcholine receptor M2 (CHRM1/CHRM2)

Target
CHRM1/CHRM2
Molecular classification
G protein-coupled receptor, Receptor, Acetylcholine receptor (muscarinic)
01

Overview

Muscarinic acetylcholine receptors M1 and M2 are G protein-coupled receptors (GPCRs) that mediate the physiological effects of the neurotransmitter acetylcholine in the central and peripheral nervous systems (UniProt P11229, P08172). The M1 receptor is predominantly expressed in the cerebral cortex and hippocampus, where it plays a vital role in cognitive functions such as learning, memory, and attention by signaling through the Gq/11 pathway (StatPearls, NIH). In contrast, the M2 receptor is the primary muscarinic subtype in the heart, regulating heart rate and contractility via the Gi/o pathway, and also serves as a presynaptic autoreceptor in the brain (Wikipedia, NIH). These receptors are significant therapeutic targets; M1 agonists and positive allosteric modulators are being investigated for the treatment of cognitive symptoms in Alzheimer's disease and schizophrenia (BMS, PubMed). M2 receptors are targeted by antagonists like atropine to treat bradycardia and are involved in the side-effect profiles of many non-selective anticholinergic drugs (StatPearls). A major challenge in drug development is achieving subtype selectivity to avoid adverse effects, such as gastrointestinal distress from M1 activation or tachycardia from M2 blockade (NIH, PubMed). Furthermore, M1 and M2 receptors are involved in the regulation of smooth muscle contraction and glandular secretions, making them relevant in respiratory and gastrointestinal medicine (NIH). The structural similarity between the five muscarinic subtypes (M1-M5) complicates the design of ligands that do not cross-react, leading to a high incidence of off-target effects (PubMed). Recent research focuses on allosteric modulators to improve selectivity and reduce the risk of receptor desensitization (NIH). Overall, M1 and M2 receptors remain central to neuropharmacology and cardiovascular medicine due to their diverse and critical physiological roles.

Other names
Cholinergic receptor muscarinic 1Cholinergic receptor muscarinic 2M1RM2RHM1HM2Muscarinic acetylcholine receptor 1Muscarinic acetylcholine receptor 2
02

Mechanism of action

The M1 receptor is Gq-coupled, activating phospholipase C to increase inositol trisphosphate (IP3) and intracellular calcium; the M2 receptor is Gi-coupled, inhibiting adenylyl cyclase to decrease cAMP and activating G protein-coupled inwardly-rectifying potassium (GIRK) channels.

03

Biological functions

Signal transductionNeurotransmissionCognitionHeart rate regulationSmooth muscle contractionGlandular secretion
04

Disease associations

Alzheimer's diseaseSchizophreniaParkinson's diseaseBradycardiaChronic obstructive pulmonary disease (COPD)Overactive bladderPeptic ulcerDepression
05

Safety considerations

Anticholinergic side effects (dry mouth, blurred vision, constipation, urinary retention)Cognitive impairment and confusion, particularly in elderly patientsCardiovascular instability (tachycardia from M2 blockade or bradycardia from M2 activation)Gastrointestinal distress (diarrhea and salivation from M1 activation)Risk of convulsions with excessive cholinergic activation
06

Interacting drugs

Atropine

11 more in the full profile.

07

Biomarkers

[11C]MK-6884 (M1 PET ligand)[18F]FP-TZTP (M2 PET ligand)[11C]LSN3172176 (M1 PET ligand)

Beyond the preview

Go deeper on Muscarinic acetylcholine receptor M1 and Muscarinic acetylcholine receptor M2 (CHRM1/CHRM2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Muscarinic acetylcholine receptor M1 and Muscarinic acetylcholine receptor M2 (CHRM1/CHRM2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call